<DOC>
	<DOCNO>NCT01432457</DOCNO>
	<brief_summary>A multicenter , 8-week study evaluate efficacy 2 dos ( 50 100 mg/day ) desvenlafaxine succinate sustained-release ( DVS SR ) versus placebo adult outpatient major depressive disorder .</brief_summary>
	<brief_title>Study Evaluating Desvenlafaxine Succinate Sustained-Release ( DVS SR ) Adult Outpatients With Major Depressive Disorder ( MDD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Male female outpatient age 18 year old fluent write spoken English . A primary diagnosis MDD base criterion Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSM IVTR ) , single recurrent episode , without psychotic feature . A HAMD17 total score â‰¥20 screen baseline ( study day 1 ) visit 4point improvement screen baseline . Significant risk suicide base clinical judgment . Current ( within 12 month baseline ) psychoactive substance abuse dependence ( include alcohol ) , manic episode , posttraumatic stress disorder , obsessive compulsive disorder , lifetime diagnosis bipolar psychotic disorder . Current generalize anxiety disorder , panic disorder , social anxiety disorder . History current evidence gastrointestinal disease know interfere absorption excretion drug history surgery know interfere absorption excretion drug . Any unstable hepatic , renal , pulmonary , cardiovascular , ophthalmologic , neurologic , severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>